PDS Biotechnology Corporation’s recent filing unveils that its Director Freitag Gregory Gene acquired Company’s shares for reported $25000.0 on Feb 28 ’25. In the deal valued at $1.66 per share,15,060 shares were bought. As a result of this transaction, Freitag Gregory Gene now holds 61,213 shares worth roughly $74067.73.
Then, Glover Stephen C. bought 15,061 shares, generating $25,001 in total proceeds. Upon buying the shares at $1.66, the Director now owns 78,851 shares.
B. Riley Securities initiated its PDS Biotechnology Corporation [PDSB] rating to a Buy in a research note published on November 01, 2022; the price target was $10. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late June with a ‘”an Overweight”‘ rating. H.C. Wainwright also remained covering PDSB and has increased its forecast on November 10, 2020 with a “Buy” recommendation from previously “Neutral” rating. Alliance Global Partners started covering the stock on May 27, 2020. It rated PDSB as “a Buy”.
Price Performance Review of PDSB
On Monday, PDS Biotechnology Corporation [NASDAQ:PDSB] saw its stock fall -9.02% to $1.21. Over the last five days, the stock has lost -4.72%. PDS Biotechnology Corporation shares have fallen nearly -25.77% since the year began. Nevertheless, the stocks have fallen -79.39% over the past one year. While a 52-week high of $6.68 was reached on 02/27/25, a 52-week low of $1.20 was recorded on 03/03/25. SMA at 50 days reached $1.5382, while 200 days put it at $2.6979.
Levels Of Support And Resistance For PDSB Stock
The 24-hour chart illustrates a support level at 1.1500, which if violated will result in even more drops to 1.0900. On the upside, there is a resistance level at 1.2800. A further resistance level may holdings at 1.3500. The Relative Strength Index (RSI) on the 14-day chart is 39.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0821, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.19%. Stochastics %K at 11.27% indicates the stock is a buying.
The most recent change occurred on March 09, 2020 when Noble Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $5.45 price target.
